natgillin/translations-raw huggingface dataset:
The concomitant use of CNS depressants including barbiturates, benzodiazepines, neuroleptics or other opioids, halogen gases or other non-selective CNS depressants (e.g. alcohol) may enhance respiratory depression.
Istodobna upotreba depresora SŽS-a, uključujući barbiturate, benzodiazepine, neuroleptike ili druge opioide, halogene plinove ili druge neselektivne depresore SŽS-a (npr. alkohol), mogu pojačati respiracijsku depresiju.
The concomitant use of crizotinib with strong CYP3A4 inhibitors or with strong and moderate CYP3A4 inducers should be avoided (see section 4.5).
Treba izbjegavati istodobnu primjenu krizotiniba sa snažnim inhibitorima CYP 3A4 ili sa snažnim ili umjerenim induktorima CYP3A4 (vidjeti dio 4.5).
The concomitant use of Cymbalta with selective, reversible MAOIs, like moclobemide, is not recommended (see section 4.4).
Ne preporučuje se istodobna primjena lijeka Cymbalta sa selektivnim reverzibilnim inhibitorima MAO, poput moklobemida (vidjeti dio 4.4).
The concomitant use of CYP3A4 inducers (i.e. rifampicin, Hypericum perforatum) may lead to a lower plasma concentration of amlodipine.
Istovremena primjena CYP3A4 induktora (tj. rifampicin, gospina trava) može dovesti do nižih koncentracija amlodipina u plazmi.
The concomitant use of cytoreductive therapies and Jakavi has not been studied.
Istodobna primjena citoreduktivnih terapija i Jakavija nije do sada proučavana.
The concomitant use of cytoreductive therapies or haematopoietic growth factors with Jakavi has not been studied.
Istodobna primjena citoreduktivnih terapija ili hematopoetskih čimbenika rasta s Jakavijem nije do sada proučavana.
The concomitant use of docetaxel with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, indinavir, nefazondone, nelfinavir, ritonavir, saquinavir, telithromycin and voriconazole) should be avoided (see section 4.5).
Treba izbjegavati istodobnu primjenu docetaksela sa snažnim inhibitorima CYP3A4 (npr. ketokonazolom, itrakonazolom, klaritromicinom, indinavirom, nefazodonom, nelfinavirom, ritonavirom, sakvinavirom, telitromicinom i vorikonazolom) (vidjeti dio 4.5).
The concomitant use of Edarbi with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 mL/min/1.73m2) (see sections 4.5 and 5.1).
Istodobna primjena Edarbija s lijekovima koji sadrže aliskiren kontraindicirana je u bolesnika sa šećernom bolešću ili oštećenjem bubrega (GFR < 60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i 5.1).
The concomitant use of Effentora with strong CYP3A4 inhibitors (e.g., ritonavir, ketoconazole, itraconazole, troleandomycin, clarithromycin, and nelfinavir) or moderate CYP3A4 inhibitors (e.g., amprenavir, aprepitant, diltiazem, erythromycin, fluconazole, fosamprenavir, grapefruit juice, and verapamil) may result in increased fentanyl plasma concentrations, potentially causing serious adverse drug reactions including fatal respiratory depression.
Istodobna primjena Effentore s jakim inhibitorima CYP3A4 (primjerice, s ritonavirom, ketokonazolom, itrakonazolom, troleandomicinom, klaritromicinom i nelfinavirom) ili umjerenim inibitorima CYP3A4 (primjerice, s amprenavirom, aprepitantom, dilitiazemom, eritromicinom, flukonazolom, fosamprenavirom, sokom od grejpfruta i verapamilom) može uzrokovati porast plazmatskih koncentracija fentanila što potencijalno uzrokuje ozbiljne nuspojave, uključujući smrtonosnu respiratornu depresiju.
The concomitant use of Eliquis with antiplatelet agents increases the risk of bleeding (see section 4.5).
Istodobna primjena lijeka Eliquis s antitromboticitnim lijekovima povećava rizik od krvarenja (vidjeti dio 4.5).
The concomitant use of Eliquis with strong CYP3A4 and P-gp inducers (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital or St. John’s Wort) may lead to a ~50% reduction in apixaban exposure.
Istodobna primjena lijeka Eliquis sa snažnim induktorima CYP3A4 i P-gp-a (npr. rifampicinom, fenitoinom, karbamazepinom, fenobarbitalom ili gospinom travom) može smanjiti izlaganje apiksabanu za ~50%.
The concomitant use of fesoterodine with a potent CYP3A4 inducer (i.e. carbamazepine, rifampicin, phenobarbital, phenytoin, St John’s Wort) is not recommended (see section 4.5).
Ne preporučuje se istovremena primjena fesoterodina s jakim induktorima CYP3A4 (tj. karbamazepinom, rifampicinom, fenobarbitalom, fenitoinom, gospinom travom) (vidjeti dio 4.5).
The concomitant use of FIRDAPSE and medicinal products with atropinic effects may reduce the effect of both active substances and should be taken into consideration.
Istodobna uporaba lijeka FIRDAPSE i lijekova s atropinskim učincima može smanjiti učinak obje djelatne tvari te to treba uzeti u obzir.
The concomitant use of FIRDAPSE and medicinal products with cholinergic effects (e.g. direct or indirect cholinesterase inhibitors) may lead to an increased effect of both products and should be taken into consideration.
Istodobna uporaba lijeka FIRDAPSE i lijekova s kolinergičkim učincima (primjerice izravnih ili neizravnih inhibitora kolinesteraze) može uzrokovati pojačani učinak oba lijeka i to treba uzeti u obzir.
The concomitant use of FIRDAPSE and medicinal products with depolarising muscle relaxant effects (e.g. suxamethonium) may lead to a decreased effect of both products and should be taken into consideration.
Istodobna primjena lijeka FIRDAPSE i lijekova s učincima depolarizirajućih miorelaksansa (primjerice suksametonij) može uzrokovati smanjeni učinak oba lijeka i to treba uzeti u obzir.
The concomitant use of FIRDAPSE and medicinal products with non-depolarising muscle relaxant effects (e.g. mivacurium, pipercurium) may lead to a decreased effect of both products and should be taken into consideration.
Istodobna primjena lijeka FIRDAPSE i lijekova s učincima nedepolarizirajućih miorelaksansa (primjerice mivakurij, piperkurij) može uzrokovati smanjeni učinak oba lijeka i to treba uzeti u obzir.
The concomitant use of Ifirmacombi with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2) (see sections 4.5 and 5.1)
Istodobna primjena Ifirmacombi s lijekovima koji sadrže aliskiren kontraindicirana je u bolesnika sa šećernom bolešću ili oštećenjem bubrega (GFR < 60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i 5.1)
The concomitant use of Ipreziv with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 mL/min/1.73m2) (see sections 4.5 and 5.1).
Istodobna primjena Ipreziv s lijekovima koji sadrže aliskiren kontraindicirana je u bolesnika sa šećernom bolešću ili oštećenjem bubrega (GFR < 60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i 5.1).
The concomitant use of Irbesaratn Zentiva with aliskiren-containing products is contraindicated in patients with diabetes mellitus or moderate to severe renal impairment (glomerular filtration rate (GFR) <60 ml/min/1.73m2) (see sections 4.5 and 5.1).
Istodobna primjena lijeka Irbesartan Zentiva s lijekovima koji sadrže aliskiren kontraindicirana je u bolesnika sa šećernom bolešću ili oštećenjem bubrega (GFR < 60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i 5.1).
The concomitant use of Irbesartan Hydrochlorothiazide Zentiva with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (glomerular filtration rate (GFR) <60 ml/min/1.73 m²) (see sections 4.5 and 5.1).
Istodobna primjena lijeka Irbesartan Hydrochlorothiazide Zentiva s lijekovima koji sadrže aliskiren kontraindicirana je u bolesnika sa šećernom bolešću ili oštećenjem bubrega (GFR < 60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i 5.1).
The concomitant use of Irbesartan Teva with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2) (see sections 4.5 and 5.1).
Istodobna primjena lijeka Irbesartan Teva s lijekovima koji sadrže aliskiren kontraindicirana je u bolesnika sa šećernom bolešću ili oštećenjem bubrega (GFR < 60 ml/1,73 m2) (vidjeti dijelove 4.5 i 5.1)
The concomitant use of Irbesartan Zentiva with aliskiren-containing products is contraindicated in patients with diabetes mellitus or moderate to severe renal impairment (glomerular filtration rate (GFR) <60 ml/min/1.73m2) (see sections 4.5 and 5.1).
Istodobna primjena lijeka Irbesartan Zentiva s lijekovima koji sadrže aliskiren kontraindicirana je u bolesnika sa šećernom bolešću ili oštećenjem bubrega (GFR < 60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i 5.1).
The concomitant use of Irbesartan/Hydrochlorothiazide Teva with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2) (see sections 4.5 and 5.1)
Istodobna primjena lijeka Irbesartan/Hidroklorotiazid Teva s lijekovima koji sadrže aliskiren kontraindicirana je u bolesnika sa šećernom bolešću ili oštećenjem bubrega (GFR < 60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i 5.1)
The concomitant use of Irbesartan/Hydrochlorothiazide Teva with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2) (see sections 4.5 and 5.1).
Istodobna primjena lijeka Irbesartan/Hidroklorotiazid Teva s lijekovima koji sadrže aliskiren kontraindicirana je u bolesnika sa šećernom bolešću ili oštećenjem bubrega (GFR < 60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i 5.1)
The concomitant use of Karvea with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (glomerular filtration rate (GFR) <60 ml/min/1.73m2) (see sections 4.5 and 5.1).
Istodobna primjena lijeka Karvea s lijekovima koji sadrže aliskiren kontraindicirana je u bolesnika sa šećernom bolešću ili oštećenjem bubrega (GFR < 60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i 5.1)..
The concomitant use of Kinzalkomb with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2) (see sections 4.5 and 5.1).
Istodobna primjena Kinzalkomba s lijekovima koji sadrže aliskiren kontraindicirana je u bolesnika sa šećernom bolešću ili oštećenjem bubrega (GFR < 60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i 5.1).
The concomitant use of MabThera and anti-rheumatic therapies other than those specified under the rheumatoid arthritis indication and posology is not recommended.
Istodobna primjena lijeka MabThera i antireumatskih lijekova koji nisu navedeni u poglavljima o indikaciji i doziranju za reumatoidni artritis se ne preporučuje.
The concomitant use of medicinal products that have been associated with renal toxicity and those eliminated by tubular secretion such as NSAIDs, amphotericin B, methotrexate, aminosides, organoplatines, foscarnet, pentamidine, cyclosporin, tacrolimus, acyclovir and valganciclovir, should be avoided particularly during the 5 day clofarabine administration period; preference should be given to those medicinal products that are not known to be nephrotoxic (see sections 4.5 and 4.8).
Treba izbjegavati istodobnu primjenu lijekova povezanih s nefrotoksičnošću i onih koji se izlučuju tubularnom sekrecijom, kao što su nesteroidni protuupalni lijekovi (NSAIL), amfotericin B, metotreksat, aminozidi, spojevi platine, foskarnet, pentamidin, ciklosporin, takrolimus, aciklovir i valganciklovir, naročito tijekom petodnevnog razdoblja primjene klofarabina; prednost treba dati onim lijekovima za koje se zna da nisu nefrotoksični (vidjeti dijelove 4.5 i 4.8).
The concomitant use of MicardisPlus with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2) (see sections 4.5 and 5.1).
Istodobna primjena MicardisPlusa s lijekovima koji sadrže aliskiren kontraindicirana je u bolesnika sa šećernom bolesti ili oštećenjem bubrega (GFR < 60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i 5.1).
The concomitant use of MicardisPlus with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2) (see sections 4.5 and 5.1).
Istodobna primjena MicardisPlusa s lijekovima koji sadrže aliskiren kontraindicirana je u bolesnika sa šećernom bolešću ili oštećenjem bubrega (GFR < 60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i 5.1).
The concomitant use of MicardisPlus with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2) (see sections 4.5 and 5.1).
Istodobna primjena MicaridsPlusa s lijekovima koji sadrže aliskiren kontraindicirana je u bolesnika sa šećernom bolešću ili oštećenjem bubrega (GFR < 60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i 5.1).
the concomitant use of monoamine oxidase inhibitors (MAOI) might produce exaggeration of the effects of opioids, based on experience with morphine.
na temelju iskustva s morfijem, istovremena primjena inhibitora monoaminooksidaze (MAOI) može pojačati učinke opioida.
The concomitant use of NSAIDs with this veterinary medicinal product may reduce its anti- hypertensive effect, its natriuretic effect and increase the level of serum potassium.
Istovremena primjena nesteroidnih protuupalnih analgetika s ovim veterinarsko-medicinskim proizvodom može smanjiti njegov antihipertenzivni i natriuretski učinak te povećati razinu serumskog kalija.
The concomitant use of Opgenra with a synthetic bone void filler is not recommended (see section 4.5).
Istovremena primjena lijeka Opgenra sa sintetskim punilom šupljina u kostima nije preporučena (vidjeti dio 4.5).
The concomitant use of other central nervous system depressants, including other opioids, sedatives or hypnotics, general anaesthetics, phenothiazines, tranquillisers, skeletal muscle relaxants, sedating antihistamines and alcohol may produce additive depressant effects.
Istovremena primjena drugih depresora središnjeg živčanog sustava uključujući druge opioide, sedative ili hipnotike, opće anestetike, fenotiazine, trankvilizatore, mišićne relaksanse, sedativne antihistaminike i alkohol može uzrokovati dodatni učinak depresora.
The concomitant use of other central nervous system depressants, including other opioids, sedatives or hypnotics, general anaesthetics, phenothiazines, tranquillisers, skeletal muscle relaxants, sedating antihistamines and alcohol may produce additive depressant effects.
Istovremena primjena drugih depresora središnjeg živčanog sustava, uključujući druge opioide, sedative ili hipnotike, opće anestetike, fenotiazine, trankvilizatore, mišićne relaksanse, sedirajuće antihistaminike i alkohol, mogu izazvati jače depresivne učinke na središnji živčani sustav.
The concomitant use of other systemic alpha adrenergic receptor agonists may potentiate the undesirable effects of this class of medicinal products in patients:
Istodobna primjena drugih sistemskih agonista alfa-adrenergičkih receptora mogu pojačati nuspojave ove klase lijekova u bolesnika:
The concomitant use of oxybutynin with other anticholinergic medicinal products or with other active substances that compete for CYP3A4 enzyme metabolism may increase the frequency or severity of dry mouth, constipation, and drowsiness.
Istodobnom primjenom oksibutinina s drugim antikolinergičkim lijekovima ili s drugim djelatnim tvarima koje se natječu za metabolizam enzima CYP3A4 može se povećati učestalost ili težina suhoće usne šupljine, konstipacije i omamljenosti.
The concomitant use of oxybutynin with other anticholinergic medicinal products or with other agents that compete for CYP3A4 enzyme metabolism may increase the frequency or severity of dry mouth, constipation, and drowsiness.
Istodobna primjena oksibutinina s drugim antikolinergičkim lijekovima ili s drugim čimbenicima koji se natječu za metabolizam enzima CYP3A4 može povećati učestalost ili težinu suhoće usne šupljine, konstipacije i omamljenosti.
The concomitant use of partial opioid agonists/antagonists (e.g. buprenorphine, nalbuphine, pentazocine) is not recommended.
Istovremena primjena parcijalnih opioidnih agonista/antagonista (primjerice, buprenorfina, nalbufina, pentazocina) se ne preporučuje.
The concomitant use of partial opioid agonists/antagonists (e.g. buprenorphine, nalbuphine, pentazocine) is not recommended.
Ne preporučuje se istodobna primjena parcijalnih opioidnih agonista/antagonista (npr. buprenorfina, nalbufina, pentazocina).
The concomitant use of Pedea with the following medicinal products is not recommended: diuretics: ibuprofen may reduce the effect of diuretics; diuretics can increase the risk of nephrotoxicity of NSAIDs in dehydrated patients.
Ne preporučuje se istodobna primjena Pedee sa sljedećim lijekovima: diureticima: ibuprofen može smanjiti učinak diuretika; diuretici mogu povećati rizik od nefrotoksičnosti NSAIL u dehidriranih bolesnika.
The concomitant use of potent CYP3A4 inhibitors (e.g., as ritonavir, ketoconazole, itraconazole, troleandomycin, clarithromycin, and nelfinavir) or moderate CYP3A4 inhibitors (e.g., amprenavir, aprepitant, diltiazem, erythromycin, fluconazole, fosamprenavir, grapefruit juice, and verapamil) with IONSYS may result in an increase in fentanyl plasma concentrations, which could increase or prolong both the therapeutic effect and adverse reactions, and may cause serious respiratory depression.
Istodobna primjena snažnih inhibitora CYP3A4 (npr. ritonavira, ketokonazola, itrakonazola, troleandomicina, klaritromicina i nelfinavira) ili umjerenih inhibitora CYP3A4 (npr. amprenavira, aprepitanta, diltiazema, eritromicina, flukonazola, fosamprenavira, soka od grejpa i verapamila) sa sustavom IONSYS može dovesti do povećanja koncentracije fentanila u plazmi, koja može pojačati ili produžiti terapijski učinak i nuspojave te dovesti do ozbiljne respiratorne depresije.
The concomitant use of potent CYP3A4 inhibitors such as azole antifungals (ketoconazole, itraconazole), macrolide antibiotics (clarithromycin, erythromycin per os, josamycin, telithromycin), HIV protease inhibitors (nelfinavir, ritonavir) and nefazodone is contra-indicated (see section 4.3).
Istodobna primjena jakih CYP3A4 inhibitora kao što su azolni antimikotici (ketokonazol, itrakonazol), makrolidni antibiotici (klaritromicin, eritromicin per os, jozamicin, telitromicin), inhibitori proteaze HIV-a (nelfinavir, ritonavir) i nefazodona je kontraindicirana (vidjeti dio 4.3).
The concomitant use of PritorPlus with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2) (see sections 4.5 and 5.1).
Istovremena primjena PritorPlusa s lijekovima koji sadrže aliskiren kontraindicirana je u bolesnika sa šećernom bolešću ili oštećenjem bubrega (GFR < 60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i 5.1).
The concomitant use of Rapamune with a calcineurin inhibitor may increase the risk of calcineurin inhibitor-induced haemolytic uraemic syndrome/thrombotic thrombocytopaenic purpura/thrombotic microangiopathy (HUS/TTP/TMA).
Istodobna primjena Rapamunea s inhibitorom kalcineurina može povećati rizik od nastanka hemolitičko-uremijskog sindroma, trombotične trombocitopenične purpure i trombotske mikroangiopatije (HUS/TTP/TMA) koji su izazvani inhibitorima kalcineurina.
The concomitant use of Rapamune with a calcineurin inhibitor may increase the risk of calcineurin inhibitor-induced haemolytic uraemic syndrome/thrombotic thrombocytopaenic purpura/thrombotic microangiopathy (HUS/TTP/TMA).
Istodobna primjena Rapamunea s inhibitorom kalcineurina može povećati rizik od nastanka hemolitičko-uremijskog sindroma, trombotične trombocitopenične purpure i trombotske mikroangiopatije (HUS/TTP/TMA) koji su izazvani inhibitorom kalcineurina.
The concomitant use of Rasilez HCT with an ACEI or an ARB is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2) (see sections 4.5 and 5.1).
Istodobna primjena Rasilez HCT-a s ACEI-ima ili ARB-ima kontraindicirana je u bolesnika sa šećernom bolešću ili oštećenjem bubrežne funkcije (GFR <60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i 5.1).
The concomitant use of Rasilez with an ACEI or an ARB is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2) (see sections 4.5 and 5.1).
Istodobna primjena Rasileza s ACEI-ima ili ARB-ima kontraindicirana je u bolesnika sa šećernom bolešću ili oštećenjem bubrežne funkcije (GFR <60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i 5.1).
The concomitant use of riociguat with other cumarin-derivatives (e.g. phenprocoumon) is also not expected to alter prothrombin time.
Ne očekuje se ni da će istodobno primjena riocigvata s drugim derivatima kumarina (npr. fenprokumonom) promijeniti protrombinsko vrijeme.
The concomitant use of riociguat with strong CYP1A1 inhibitors, such as the tyrosine kinase inhibitor erlotinib, and strong P-glycoprotein (P-gp) / breast cancer resistance protein (BCRP) inhibitors, such as the immuno-suppressive agent cyclosporine A, may increase riociguat exposure (see section 4.5 and 5.2).
Istodobna primjena riocigvata s jakim inhibitorima CYP1A1, kao što je inhibitor tirozin-kinaze erlotinib, i jakim inhibitorima P-glikoproteina (P-gp)/proteina za rezistenciju na karcinom dojke (BCRP), kao što je imunosupresiv ciklosporin A, može povećati izloženost riocigvatu (vidjeti dijelove 4.5 i 5.2).
The concomitant use of riociguat with strong CYP1A1 inhibitors, such as the tyrosine kinase inhibitor erlotinib, and strong P-glycoprotein (P-gp) / breast cancer resistance protein (BCRP) inhibitors, such as the immuno-suppressive agent cyclosporine A, may increase riociguat exposure (see section 4.5 and 5.2).
Istodobnaa primjena riocigvata s jakim inhibitorima CYP1A1, kao što je inhibitor tirozin-kinaze erlotinib, i jakim inhibitorima P-glikoproteina (P-gp)/proteina za rezistenciju na karcinom dojke (BCRP), kao što je imunosupresiv ciklosporin A, može povećati izloženost riocigvatu (vidjeti dijelove 4.5 i 5.2).
The concomitant use of riociguat with strong CYP1A1 inhibitors, such as the tyrosine kinase inhibitor erlotinib, and strong P-glycoprotein (P-gp) / breast cancer resistance protein (BCRP) inhibitors, such as the immuno-suppressive agent cyclosporine A, may increase riociguat exposure (see section 4.5 and 5.2).
Istovremena primjena riocigvata s jakim inhibitorima CYP1A1, kao što je inhibitor tirozin- kinaze erlotinib, i jakim inhibitorima P-glikoproteina (P-gp)/proteina za rezistenciju na karcinom dojke (BCRP), kao što je imunosupresiv ciklosporin A, može povećati izloženost riocigvatu (vidjeti dijelove 4.5 i 5.2).
The concomitant use of riociguat with strong CYP3A4 inducers (e.g. phenytoin, carbamazepine, phenobarbitone or St. John’s Wort) may also lead to decreased riociguat plasma concentration.
Istodobna primjena riocigvata s jakim induktorima CYP3A4 (npr. fenitoinom, karbamazepinom, fenobarbitonom ili gospinom travom) također može dovesti do sniženja koncentracije riocigvata u plazmi.
The concomitant use of riociguat with strong multi pathway cytochrome P450 (CYP) and P- glycoprotein (P-gp) / breast cancer resistance protein (BCRP) inhibitors such as azole antimycotics (e.g. ketoconazole, itraconazole) or HIV protease inhibitors (e.g. ritonavir) is not recommended, due to the pronounced increase in riociguat exposure (see section 4.5 and 5.2).
Ne preporučuje se istodobna primjena riocigvata s jakim inhibitorima višestrukih puteva citokroma P450 (CYP) i P-glikoproteina (P-gp)/proteina za rezistenciju na karcinom dojke (BCRP) poput azolnih antimikotika (npr. ketokonazol, itrakonazol) ili inhibitorima HIV proteaze (npr. ritonavirom) zbog izrazitog povećanja izloženosti riocigvatu (vidjeti dijelove 4.5 i 5.2).
The concomitant use of riociguat with strong multi pathway cytochrome P450 (CYP) and P- glycoprotein (P-gp) / breast cancer resistance protein (BCRP) inhibitors such as azole antimycotics (e.g. ketoconazole, itraconazole) or HIV protease inhibitors (e.g. ritonavir) is not recommended, due to the pronounced increase in riociguat exposure (see section 4.5 and 5.2).
Ne preporučuje se istodobna primjena riocigvata s jakim inhibitorima višestrukih puteva citokroma P450 (CYP) i P-glikoproteina (P-gp)/proteina za rezistenciju na karcinom dojke (BCRP) poput azolnih antimikotika (npr. ketokonazol, itrakonazol) ili inhibitorima HIV proteaze (npr. ritonavirom) zbog izrazitog povećanja izloženosti riocigvatu (vidjeti dio 4.5 i 5.2).